ISOPTO CETAPRED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOPTO CETAPRED (ISOPTO CETAPRED).
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
| Metabolism | Sulfacetamide: hepatic acetylation; Prednisolone: hepatic metabolism via CYP3A4 |
| Excretion | Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates. |
| Half-life | Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects. |
| Protein binding | Sulfacetamide: ~50% bound to albumin; Prednisolone: 70-90% bound (corticosteroid-binding globulin and albumin). |
| Volume of Distribution | Sulfacetamide: 0.15-0.30 L/kg; Prednisolone: 0.4-0.7 L/kg. Both distribute well into ocular tissues. |
| Bioavailability | Ocular: sulfacetamide bioavailability is ~10-20% of applied dose (systemic); prednisolone ocular bioavailability is ~10-15% (systemic). Oral: not applicable. |
| Onset of Action | Ocular administration: sulfacetamide achieves bacteriostatic levels within 30 minutes; prednisolone anti-inflammatory effect begins within 1-2 hours. |
| Duration of Action | Ocular: sulfacetamide bacteriostatic effect persists 4-6 hours; prednisolone anti-inflammatory effect lasts 6-12 hours (dose-dependent). |
| Molecular Weight | Prednisolone: 360.44 Da; Sulfacetamide: 214.24 Da |
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
| Dosage form | SUSPENSION |
| Renal impairment | No dosage adjustment required due to negligible systemic absorption after topical ophthalmic administration. |
| Liver impairment | No specific hepatic adjustment required; ophthalmic use results in minimal systemic exposure. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use only if potential benefit justifies risk. No specific weight-based guidelines available. |
| Geriatric use | Elderly patients may be more susceptible to adverse effects (e.g., increased intraocular pressure); use with caution and monitor intraocular pressure regularly. |
| 1st trimester | Corticosteroids and sulfonamides are generally avoided in first trimester due to risk of cleft palate and congenital malformations, respectively. However, if benefits outweigh risks, use with caution. |
| 2nd trimester | Use only if clearly needed. Corticosteroids may increase risk of maternal infection and fetal growth restriction; sulfonamides may cause kernicterus if used near term. |
| 3rd trimester | Avoid sulfonamides in the last month of pregnancy due to risk of kernicterus. Corticosteroids should be used with caution; may cause adrenal suppression in neonate. |
Clinical note
Comprehensive clinical and safety monograph for ISOPTO CETAPRED (ISOPTO CETAPRED).
| Placental transfer | Both components cross the placenta. Prednisolone is approximately 90% bound to transcorin and albumin, limiting transfer; sulfacetamide crosses freely and competes for bilirubin binding sites. |
| Breastfeeding | Both prednisolone and sulfacetamide are excreted in breast milk in small amounts. Prednisolone is considered compatible with breastfeeding at low doses, but sulfacetamide may cause hemolytic anemia in G6PD-deficient infants or kernicterus in jaundiced infants. Avoid in breastfeeding mothers with history of G6PD deficiency or infant jaundice. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component (prednisolone or sulfacetamide) or sulfonamidesActive untreated bacterial, fungal, or viral ocular infections (except for appropriate antimicrobial therapy)Varicella or vaccinia (risk of severe systemic infection)Glaucoma (may increase intraocular pressure)Post-operative corneal thinning or epithelial defects (risk of perforation)
| Precautions | Prolonged use may lead to cataracts, glaucoma, or secondary infections (including fungal)., May mask signs of infection or cause exacerbation of infections., Sulfonamide hypersensitivity reactions possible., Monitor intraocular pressure if used for 10+ days., Not for use in viral or fungal infections of the eye. |
| Food/Dietary | No specific food interactions reported. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Corticosteroids are associated with a small increased risk of oral clefts (absolute risk ~0.1-0.3%). Second and third trimesters: No proven teratogenic risk; possible fetal growth restriction with systemic use, but ophthalmic administration results in negligible systemic absorption. |
| Fetal Monitoring | Monitor intraocular pressure, visual acuity, and corneal integrity. In pregnancy, monitor for signs of fetal growth restriction if prolonged high-dose systemic exposure occurs (unlikely with ophthalmic use). |
| Fertility Effects | No direct evidence of impaired fertility in humans; animal studies with high doses show some reproductive effects, but ophthalmic route minimizes systemic exposure. |
| Clinical Pearls | ISOPTO CETAPRED contains sulfacetamide sodium (antibacterial) and prednisolone acetate (corticosteroid). Use with caution in patients with glaucoma due to potential intraocular pressure elevation. Do not use in patients with epithelial herpes simplex keratitis or fungal infections. Shake well before use to suspend the steroid component. Monitor for corneal thinning with prolonged use. |
| Patient Advice | Shake the bottle well before each use. · Tilt head back, pull down lower eyelid, and instill drop without touching the eye. · Wait 10 minutes before inserting contact lenses (do not wear lenses during treatment). · Do not share the medication with others to prevent infection. · Report any eye pain, vision changes, or worsening redness to your doctor immediately. · Use only as prescribed; do not use for longer than recommended due to steroid risks. |